NR3C1 and breast cancer: In estrogen receptor (ER)-negative breast cancers, including triple-negative breast cancer and in prostate cancer, expression levels of GR correlate with bad prognosis of chemotherapy-treated patients, suggesting a role for GR in tumour aggressiveness and resistance to drug treatment25, 47, 48.